SELLAS Life Sciences (SLS) Operating Margin (2012 - 2022)
SELLAS Life Sciences (SLS) reported Operating Margin of 1673.5% for Q1 2022, down 163411.0% year-over-year from N/an in Q1 2021, and down 614.05% quarter-over-quarter from 234.37% in Q2 2021.
SELLAS Life Sciences (SLS) Operating Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has 7 years of Operating Margin data on file, last reported at 1673.5% in Q1 2022.
- Operating Margin for Q1 2022 came in at 1673.5%, down 163411.0% year-over-year; the trailing twelve-month figure through Dec 2022 was 4195.0% (down 386218.0% YoY), and the FY2022 annual result was 4195.0%, down 386218.0% from the prior year.
- Operating Margin slipped to 1673.5% in Q1 2022 per SLS's latest filing, from 234.37% in the prior quarter.
- Over five years, Operating Margin peaked at 39.39% in Q1 2021 and troughed at 1673.5% in Q1 2022.
- A 3-year average of 541.54% and a median of 226.63% in 2021 frame the typical range for Operating Margin.
- On a YoY basis, Operating Margin climbed as much as 163411 bps in 2022 and fell as far as 163411 bps in 2022.
- A 3-year view of Operating Margin shows it stood at 218.89% in 2020, then retreated by 7 bps to 234.37% in 2021, then slumped by 614 bps to 1673.5% in 2022.
- Business Quant data shows SLS's Operating Margin at 1673.5% in Q1 2022, 234.37% in Q2 2021, and 39.39% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -1,673.50% |
| Jun 30, 2021 | -234.37% |
| Mar 31, 2021 | -39.39% |
| Dec 31, 2020 | -218.89% |
| Jun 30, 2015 | -268.57% |
| Mar 31, 2015 | -324.07% |
| Dec 31, 2014 | -303.38% |
| Sep 30, 2014 | -652.28% |
| Jun 30, 2014 | -677.09% |
| Mar 31, 2014 | -545.28% |
| Dec 31, 2013 | -219.06% |
| Sep 30, 2013 | -425.49% |
| Jun 30, 2013 | -342.60% |
| Mar 31, 2013 | -304.23% |
| Dec 31, 2012 | 476.75% |
| Sep 30, 2012 | -472.48% |